• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Management of hepatitis B reactivation in patients receiving cancer chemotherapy.乙型肝炎病毒再激活患者在接受癌症化疗时的管理。
Therap Adv Gastroenterol. 2012 Sep;5(5):359-70. doi: 10.1177/1756283X12450245.
2
Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance.预防性拉米夫定对淋巴瘤化疗相关乙型肝炎再激活的影响：已发表临床试验的荟萃分析及关于长期预防和维持治疗的决策树分析
Haematologica. 2009 Jul;94(7):998-1005. doi: 10.3324/haematol.2009.005819. Epub 2009 May 19.
3
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.接受抗癌治疗的血液系统恶性肿瘤患者中乙型肝炎病毒再激活的预防与管理
World J Gastroenterol. 2016 Jul 28;22(28):6484-500. doi: 10.3748/wjg.v22.i28.6484.
4
Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.拉米夫定治疗预防乙肝表面抗原携带者免疫抑制诱导的乙肝病毒再激活
Blood. 2002 Jul 15;100(2):391-6. doi: 10.1182/blood.v100.2.391.
5
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.对接受化疗的慢性乙肝表面抗原携带者伴发淋巴系统恶性肿瘤患者，使用拉米夫定进行乙肝病毒再激活的一级预防。
Br J Haematol. 2001 Oct;115(1):58-62. doi: 10.1046/j.1365-2141.2001.03099.x.
6
Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.拉米夫定预防恶性肿瘤乙型肝炎病毒携带者化疗诱导的乙型肝炎病毒再激活。
J Viral Hepat. 2004 Mar;11(2):141-7. doi: 10.1046/j.1365-2893.2003.00479.x.
7
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.恩替卡韦与拉米夫定预防未治疗弥漫性大 B 细胞淋巴瘤接受 R-CHOP 化疗患者乙型肝炎病毒再激活：一项随机临床试验。
JAMA. 2014 Dec 17;312(23):2521-30. doi: 10.1001/jama.2014.15704.
8
Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.拉米夫定预防化疗引起的乙型肝炎病毒感染再激活
J Clin Gastroenterol. 2003 Jul;37(1):68-71. doi: 10.1097/00004836-200307000-00017.
9
The difficulties of managing severe hepatitis B virus reactivation.管理乙型肝炎病毒再激活的困难。
Liver Int. 2011 Jan;31 Suppl 1:104-10. doi: 10.1111/j.1478-3231.2010.02396.x.
10
Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.接受化疗的乳腺癌患者中的乙型肝炎病毒再激活：预防管理的综述与荟萃分析
J Viral Hepat. 2017 Jul;24(7):561-572. doi: 10.1111/jvh.12672. Epub 2017 Feb 5.

引用本文的文献

1
Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy.在接受全身抗癌治疗的患者中实施乙肝筛查项目。
Curr Oncol. 2024 Dec 30;32(1):20. doi: 10.3390/curroncol32010020.
2
Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency Evaluation.美国新诊断癌症患者的普遍病毒筛查：成本效益评估。
Cancer Res Commun. 2023 Sep 28;3(9):1959-1965. doi: 10.1158/2767-9764.CRC-23-0255.
3
Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis.核苷酸类似物（NAs）在预防化疗或手术后HBV感染的肿瘤患者病毒再激活中的疗效：一项网状Meta分析。
Front Oncol. 2023 Jan 16;12:1050714. doi: 10.3389/fonc.2022.1050714. eCollection 2022.
4
Case Report: Vaccination by Autologous CD16 Dendritic Cells and Anti-PD-L 1 Antibody Synergized With Radiotherapy To Boost T Cells-Mediated Antitumor Efficacy In A Psoriatic Patient With Cutaneous Squamous Cell Carcinoma.病例报告：自体 CD16 树突状细胞疫苗接种联合抗 PD-L1 抗体与放射治疗协同作用，增强 T 细胞介导的抗肿瘤疗效，用于治疗患有皮肤鳞状细胞癌的银屑病患者。
Front Immunol. 2021 Dec 23;12:752563. doi: 10.3389/fimmu.2021.752563. eCollection 2021.
5
Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan.台湾地区 Bcr-Abl 酪氨酸激酶抑制剂与乙型肝炎病毒再激活需要抗病毒治疗的相关性研究。
JAMA Netw Open. 2021 Apr 1;4(4):e214132. doi: 10.1001/jamanetworkopen.2021.4132.
6
RFX1 participates in doxorubicin-induced hepatitis B virus reactivation.RFX1 参与阿霉素诱导的乙型肝炎病毒再激活。
Cancer Med. 2018 May;7(5):2021-2033. doi: 10.1002/cam4.1468. Epub 2018 Mar 30.
7
Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C.接受直接抗病毒药物治疗丙型肝炎的患者中乙肝再激活的风险。
World J Gastroenterol. 2017 Jun 28;23(24):4317-4323. doi: 10.3748/wjg.v23.i24.4317.
8
Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).实体瘤和血液系统恶性肿瘤患者的抗病毒预防——德国血液学和医学肿瘤学会（DGHO）传染病工作组（AGIHO）指南更新
Ann Hematol. 2015 Sep;94(9):1441-50. doi: 10.1007/s00277-015-2447-3. Epub 2015 Jul 21.
9
Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis.拉米夫定对乳腺癌化疗所致乙型肝炎病毒再激活的预防作用：一项Meta分析
PLoS One. 2015 Jun 9;10(6):e0128673. doi: 10.1371/journal.pone.0128673. eCollection 2015.
10
Primary seronegative but molecularly evident hepadnaviral infection engages liver and induces hepatocarcinoma in the woodchuck model of hepatitis B.原发性血清学阴性但分子学上明确的嗜肝病毒感染在土拨鼠乙型肝炎模型中累及肝脏并诱发肝癌。
PLoS Pathog. 2014 Aug 28;10(8):e1004332. doi: 10.1371/journal.ppat.1004332. eCollection 2014 Aug.

本文引用的文献

1
Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients.因化疗引起的乙型肝炎病毒再激活导致淋巴瘤患者发生急性肝衰竭而进行的肝移植。
World J Gastroenterol. 2011 Jul 7;17(25):3069-72. doi: 10.3748/wjg.v17.i25.3069.
2
Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors.在开始接受实体瘤化疗的患者中进行乙型肝炎病毒普遍筛查的成本效益。
J Clin Oncol. 2011 Aug 20;29(24):3270-7. doi: 10.1200/JCO.2011.35.1635. Epub 2011 Jul 25.
3
Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.乙肝表面抗原阴性/乙肝核心抗体阳性患者接受利妥昔单抗联合化疗而未常规进行抗病毒预防时乙型肝炎病毒（HBV）再激活的风险。
Ann Hematol. 2011 Oct;90(10):1219-23. doi: 10.1007/s00277-011-1241-0. Epub 2011 Apr 26.
4
Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.术后接受基于蒽环类药物的辅助化疗的乳腺癌患者中，预防性应用拉米夫定治疗乙型肝炎恶化。
Br J Cancer. 2011 Feb 15;104(4):559-63. doi: 10.1038/bjc.2011.4. Epub 2011 Feb 1.
5
Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy.恩替卡韦和拉米夫定在预防淋巴瘤患者化疗期间乙型肝炎病毒再激活中的比较。
J Viral Hepat. 2011 Dec;18(12):877-83. doi: 10.1111/j.1365-2893.2010.01386.x. Epub 2010 Nov 5.
6
Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy.在利妥昔单抗为基础的化疗时代的乙型肝炎病毒筛查、预防和再激活。
Liver Int. 2011 Mar;31(3):330-9. doi: 10.1111/j.1478-3231.2010.02332.x. Epub 2010 Aug 25.
7
When treating cancer, please don't forget hepatitis B.在治疗癌症时，请不要忘记乙型肝炎。
Oncologist. 2010;15(8):826-9. doi: 10.1634/theoncologist.2009-0282. Epub 2010 Jul 20.
8
Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.利妥昔单抗治疗后 CD20 阳性 B 细胞淋巴瘤患者乙型肝炎病毒再激活。
Cancer. 2010 Oct 15;116(20):4769-76. doi: 10.1002/cncr.25253.
9
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.美国临床肿瘤学会临时临床意见：恶性疾病治疗中接受细胞毒性化疗患者的慢性乙型肝炎病毒感染筛查。
J Clin Oncol. 2010 Jul 1;28(19):3199-202. doi: 10.1200/JCO.2010.30.0673. Epub 2010 Jun 1.
10
Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.HBsAg 阴性/抗-HBc 阳性的弥漫性大 B 细胞淋巴瘤患者化疗期间乙型肝炎病毒再激活发生率低：一项多中心回顾性研究。
Eur J Haematol. 2010 Sep;85(3):243-50. doi: 10.1111/j.1600-0609.2010.01474.x. Epub 2010 May 20.

乙型肝炎病毒再激活患者在接受癌症化疗时的管理。

Management of hepatitis B reactivation in patients receiving cancer chemotherapy.

机构信息

Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

出版信息

Therap Adv Gastroenterol. 2012 Sep;5(5):359-70. doi: 10.1177/1756283X12450245.

DOI:10.1177/1756283X12450245
PMID:22973419
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3437537/
Abstract

Hepatitis B virus (HBV) reactivation is well documented in previously resolved or inactive HBV carriers who receive cancer chemotherapy. The consequences of HBV reactivation range from self-limited conditions to fulminant hepatic failure and death. HBV reactivation also leads to premature termination of chemotherapy or delay in treatment schedules. This review summarizes current knowledge of management of HBV reactivation in patients receiving cancer chemotherapy. HBV surface antigen (HBsAg) testing should be performed in patients who require cancer chemotherapy. Four meta-analyses support lamivudine prophylaxis for HBV reactivation during chemotherapy in HBsAg-positive patients. Randomized controlled trials to compare different HBV antiviral agents are needed to define optimal regimens for the prevention and treatment of HBV reactivation in patients receiving cancer chemotherapy.

摘要

乙型肝炎病毒 (HBV) 再激活在既往已缓解或无活动的 HBV 携带者中已有充分记录，这些携带者在接受癌症化疗时会发生 HBV 再激活。HBV 再激活的后果从自限性疾病到暴发性肝衰竭和死亡不等。HBV 再激活还会导致化疗提前终止或治疗计划延迟。这篇综述总结了目前在接受癌症化疗的患者中管理 HBV 再激活的知识。需要接受癌症化疗的患者应进行乙型肝炎表面抗原 (HBsAg) 检测。四项荟萃分析支持在 HBsAg 阳性患者中使用拉米夫定预防化疗期间的 HBV 再激活。需要进行随机对照试验来比较不同的乙型肝炎抗病毒药物，以确定用于预防和治疗接受癌症化疗的患者的 HBV 再激活的最佳方案。